Daewoong and Recipharm extend API deal; U.K.'s national bio lab equipped for continuous manufacturing;

> Private equity is making money buying and selling contract manufacturers, a new report shows. Report

> Korea-based Daewoong has extended for 10 years a contract in which it will buy a minimum of €25 million worth of the API for its respiratory drug Erdosteine from Swedish CDMO Recipharm. Release

> The U.K.'s Centre for Process Innovation (CPI) says it and French CDMO Novasep have equipped the U.K.'s National Biologics Manufacturing Centre with Novasep's BioSC Lab to be used for continuous manufacturing. Release

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.